Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature.

MB, Ranke; A, Lindberg; DA, Price; F, Darendeliler; K, Albertsson-Wikland; P, Wilton; EO, Reiter

doi:10.1159/000098707

Public

Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature.

Shared by NobleBlocks on Jan 16, 2007 • 12:00 AM UTC

Authors:

Ranke MB

Lindberg A

Price DA

Abstract

<h4>Aim</h4>To develop methods to identify factors associated with a favorable outcome in GH-treated children with idiopathic short stature (ISS).<h4>Methods</h4>From 4,685 children listed as having ISS within KIGS (Pfizer International Growth Database), we studied (a) the prediction model group (n ...

Discussions